EUVIMEDEUVIMED entdecken
Crossref

Patient‐Reported Symptom Burden and Objective Responses After Belumosudil in Heavily Pretreated Chronic GvHD

Sergio Rodriguez-Rodriguez iD, Jennifer White, Kylie Lepic, Nihar Desai, Brittany Salter, Mohamed Elemary iD, Eshrak Al-Shaibani iD, Tommy Alfaro-Moya iD, Arjun D Law iD, Igor Novitzky-Basso iD, Ivan Pasic iD, Auro Viswabandya iD und 4 weitere

European Journal of Haematology · 11.11.2026

DOI: 10.1111/ejh.70355 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Haematology, online erschienen am 11.11.2026. Verfasst von Sergio Rodriguez-Rodriguez und 15 weiteren Autor:innen. Beteiligte Einrichtung: University Health Network, Princess Margaret Cancer Centre, Toronto, Ontario, Canada. Die Arbeit nennt 29 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Belumosudil has demonstrated clinical activity in chronic graft‐versus‐host disease (cGvHD), but its impact on patient‐reported symptom burden in routine practice remains incompletely characterized.

Objective

To evaluate longitudinal changes in cGvHD‐related symptom burden during belumosudil‐containing therapy, using the modified Lee symptom score (mLSS).

Methods

This retrospective, multicenter study included 87 heavily pretreated patients with cGvHD from four Canadian centers. We scored the mLSS at baseline and 3, 6, and 12 months after belumosudil initiation. Clinically meaningful improvement (CMI) was a ≥ 6‐point reduction in the overall mLSS. We analyzed longitudinal changes using a linear mixed‐effects model.

Results

Item‐level data were available for 48 patients (55%). Mean ± standard error mLSS decreased from 25.4 ± 1.8 at baseline to 16.5 ± 2.3 ( n = 25), 14.6 ± 3.0 ( n = 14), and 15.6 ± 4.5 ( n = 8) at 3, 6, and 12 months ( p < 0.001). CMI occurred in 52%, 64%, and 50% of evaluable patients, but in 15%, 10%, and 5% of all 87 treated patients. Best CMI was 65% ( n = 17/26) of evaluable patients and 20% of all treated patients, and best overall response rate was 41% ( n = 32/78).

Conclusions

Belumosudil‐containing therapy was associated with reduced symptom burden among patients with evaluable item‐level data. Declining data capture limits conclusions about durability and generalizability; prospective studies with systematic symptom burden capture are needed.

Schlagwörter

Stichwörter der Autor:innen

Lee symptom scorebelumosudilchronic graft‐versus‐host diseasehematopoietic cell transplantationreal‐world experiencesteroid‐refractory chronic GvHD

Autor:innen und Institutionen

  • University Health Network, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.
  • University of Toronto, Toronto, Ontario, Canada.
  • British Columbia Cancer Agency, Vancouver General Hospital, Vancouver, British Columbia, Canada.
  • University of British Columbia, Vancouver, British Columbia, Canada.
  • Hamilton Health Sciences, Juravinski Cancer Centre, Hamilton, Ontario, Canada.
  • McMaster University, Hamilton, Ontario, Canada.

ORCID-Profile: Sergio Rodriguez-Rodriguez, Mohamed Elemary, Eshrak Al-Shaibani, Tommy Alfaro-Moya, Arjun D Law, Igor Novitzky-Basso, Ivan Pasic, Auro Viswabandya, Fotios V Michelis, Rajat Kumar, Jonas Mattsson, Dennis D H Kim

Zitieren

APA

Rodriguez-Rodriguez, S., White, J., Lepic, K., Desai, N., Salter, B., Elemary, M., Al-Shaibani, E., Alfaro-Moya, T., Law, A. D., Novitzky-Basso, I., Pasic, I., Viswabandya, A., Michelis, F. V., Kumar, R., Mattsson, J., & Kim, D. D. H. (2026). Patient‐Reported Symptom Burden and Objective Responses After Belumosudil in Heavily Pretreated Chronic GvHD. European Journal of Haematology. https://doi.org/10.1111/ejh.70355

Vancouver

Rodriguez-Rodriguez S, White J, Lepic K, Desai N, Salter B, Elemary M, et al. Patient‐Reported Symptom Burden and Objective Responses After Belumosudil in Heavily Pretreated Chronic GvHD. European Journal of Haematology. 2026. doi:10.1111/ejh.70355

BibTeX
@article{RodriguezRodriguez2026,
  author = {Rodriguez-Rodriguez, Sergio and White, Jennifer and Lepic, Kylie and Desai, Nihar and Salter, Brittany and Elemary, Mohamed and Al-Shaibani, Eshrak and Alfaro-Moya, Tommy and Law, Arjun D and Novitzky-Basso, Igor and Pasic, Ivan and Viswabandya, Auro and Michelis, Fotios V and Kumar, Rajat and Mattsson, Jonas and Kim, Dennis D H},
  title = {Patient‐Reported Symptom Burden and Objective Responses After Belumosudil in Heavily Pretreated Chronic GvHD},
  journal = {European Journal of Haematology},
  year = {2026},
  doi = {10.1111/ejh.70355}
}
Kostenlos starten →